Nanoparticles in medicine: Current challenges facing inorganic nanoparticle toxicity assessments and standardizations

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 7, 2015, Pages 1689-1694

  Hofmann Amtenbrink, Margarethe ^a   Grainger, David W ^b   Hofmann, Heinrich ^c  

^a Mat Search Consulting   (Switzerland)

^b UNIVERSITY OF UTAH   (United States)

^c EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NANOMATERIAL; NANOPARTICLE; INORGANIC COMPOUND;

CLINICAL TRIAL (TOPIC); HUMAN; IN VITRO STUDY; KNOWLEDGE; NANOMEDICINE; NANOTECHNOLOGY; NANOTOXICOLOGY; NONHUMAN; NOTE; PATIENT SAFETY; RISK ASSESSMENT; STANDARDIZATION; TOXICITY TESTING; ADVERSE EFFECTS; DRUG DELIVERY SYSTEM; STANDARDS;

DRUG DELIVERY SYSTEMS; HUMANS; INORGANIC CHEMICALS; NANOMEDICINE; NANOPARTICLES;

EID: 84942123875     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.05.005     Document Type: Note

References (17)

1. http://nanomedjournal.com/content/meetingsummaries.
2. Grainger D.W., Castner D.G. Nanobiomaterials and nanoanalysis: how to improve the nanoscience for biotechnology. Adv Mater 2008, 20:867-877.
3. Gwinn M.R., Sokull-Klüttgen B. Regulation and legislation. Adverse Effects of Engineered Nanomaterials: Exposure, Toxicology, and Impact on Human Health 2012, 97-120. London Academic Press. 1st edit. B. Fadeel, A. Pietroiusti, A. Shvedova (Eds.).
4. Stern S.T., McNeil S.E. Nanotechnology safety concerns revisited. Toxicol Sci 2008, 10:4-21.
5. Duda G.N., Grainger D.W., Frisk M.L., Bruckner-Tuderman L., Carr A., Dirnagl U., et al. Changing the mindset in life sciences toward translation: A consensus. Sci Transl Med 2014, 6:264cm12.
6. [April 2015]. http://www.ccmx.ch/projects-amp-partners/past-projects/.
7. [April 2015]. http://www.nanoobjects.info/.
8. Perkel J.M. Curing cell lines. BioTechniques 2011, 51:85-90.
9. He C., Hu Y., Yin L., Tang C., Yi C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010, 13:3657-3666.
10. Oberdörster G., Stone V., Donaldson K. Toxicology of nanoparticles: A historical perspective. Nanotoxicology 2007, 1:2-25.
11. Bhattacharya S., Zhang Q., Carmichael P.L., Boekelheide K., Andersen M.E. Toxicity testing in the 21st century: Defining new risk assessment approaches based on perturbation of intracellular toxicity pathways. PLoS One 2011, 6:e20887.
12. Andersen M.E., Al-Zoughool M., Croteau M., Westphal M., Krewski D. The future of toxicity testing. J Toxicol Environ Health B Crit Rev 2010, 13:163-196.
13. Nanomaterials: Commission proposes case by case approach to assessment [April 2015]. http://europa.eu/rapid/press-release_MEMO-12-732_en.htm.
14. Grainger D.W., van der Mei H.C., Jutte P.C., van den Dungen J.J.A.M., Schultz M.J., van der Laan B.F.A.M., et al. Critical factors in the translation of improved antimicrobial strategies for medical implants and devices. Biomaterials 2013, 34:9237-9243.
15. [April 2015]. http://www.is.cityu.edu.hk/staff/isrobert/phd/ch3.pdf.
16. Contribution of Nanomedicine to Horizon 2020 NANOMEDICINE 2020, [April 2015]. http://www.etp-nanomedicine.eu/.
17. Full list of participants is given in . http://nanomedjournal.com/content/meetingsummaries.